Preclinical studies suggested that in NSCLC cell lines, one mechanism of resistance to vorinostat monotherapy is an increase in transcriptional activity of NF-kB involving the Akt pathway (Mayo et al., 2003). The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.